Positron Emission Tomography (PET) is a non-invasive molecular imaging technique that enables visualization and quantification of pathological processes in the living brain. In Alzheimer's disease (AD) research, PET imaging has become indispensable for detecting amyloid-beta plaques, tau neurofibrillary tangles, glucose metabolism, and other biomarkers associated with neurodegeneration[1][2].
PET imaging works by detecting positrons emitted from radiolabeled tracer molecules administered to the patient. The most common tracers used in AD research include:
Tau PET imaging allows for in vivo visualization of neurofibrillary tangle distribution, which closely correlates with clinical symptoms and disease progression[3][4]:
Amyloid PET detects the accumulation of amyloid-beta plaques in the brain[5]:
18FFDG PET measures cerebral glucose metabolism:
| Tracer | Target | Key Features |
|---|---|---|
| 18Fflortaucipir | Tau (NFTs) | High binding affinity; approved for clinical use |
| 18FFDG | Glucose metabolism | Widely available; measures neuronal activity |
| 11CPiB | Amyloid plaques | High amyloid specificity; short half-life |
| 18FTHK5317 | Tau | Good kinetics; early stage detection potential |
PET imaging provides critical information for:
PET endpoints are commonly used in AD clinical trials:
Despite its value, PET imaging has limitations:
The study of Positron Emission Tomography In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Regional tau deposition measured by [18F]THK5317 positron emission tomography. ↩︎
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. ↩︎
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. ↩︎
Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of tau pathology. ↩︎
Tau positron emission tomographic imaging in aging and early Alzheimer disease. ↩︎